Praxis Precision Medicines, Inc. (PRAX)
$243.34-3.20%Close
SELLCRISIS · day 21
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $6.8B
- Beta
- 2.81
- P/E (TTM)
- -18.79
- Short % float
- 13.73%
- Days to cover
- 7.2
- SI change
- +10.3%
- 1W
- -13.14%
- 1M
- -26.38%
- vs SPY 1W
- -13.00%
- vs SPY 1M
- -28.89%
Industry peers
FMP comparable companies · ranked by market cap
- NBIXSELLNeurocrine Biosciences, Inc.$13.6BRECOVERYQ 16$135.13-4.41%
- AXSMSELLAxsome Therapeutics, Inc.$8.0BCRISISQ 34$156.32-5.83%
- XENESELLXenon Pharmaceuticals Inc.$3.3BCRISISQ 22$34.42-3.88%
- ACADSELLAcadia Pharmaceuticals Inc.$3.2BCRISISQ 17$18.62-4.07%
- DNLISELLDenali Therapeutics Inc.$2.9BCRISISQ 8$18.40-2.90%
- SUPNBUYSupernus Pharmaceuticals, Inc.$2.4BRECOVERYQ 26$42.01-1.87%
- RAPPSELLRapport Therapeutics, Inc. Common Stock$1.4BCRISISQ 24$28.99-3.85%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on PRAX?
- LOPJLB’s latest quantitative signal on Praxis Precision Medicines, Inc. (PRAX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is PRAX in?
- Praxis Precision Medicines, Inc. (PRAX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Praxis Precision Medicines, Inc. (PRAX) do?
- Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the G…